ImmunologybioRxivPreprint
Tarloxotinib targets tumor hypoxia to improve therapeutic efficacy of immune checkpoint inhibition in a TLR9 dependent manner
Zhe Fu, Victoria Jackson-Patel, Kathryn J. Farrand…·Adam Vorn Patterson
This paper shows that tarloxotinib, a hypoxia-activated prodrug, reduces tumor hypoxia and enhances immune checkpoint inhibitor efficacy through TLR9-dependent mechanisms in multiple tumor models.
DOI 10.1101/2025.02.24.635378